ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis plans vaccines plant

July 24, 2006 | APPEARED IN VOLUME 84, ISSUE 30

Novartis is planning what it calls the first U.S. plant for cell-culture-derived influenza vaccines, at a site in Holly Springs, N.C. The company says construction will begin in 2007; when the plant is completed and approved for commercial production, it will have capacity to produce up to 50 million doses of seasonal flu vaccine. The plant is expected to cost $600 million, which includes a recent $220 million award from the Department of Health & Human Services (C&EN, May 8, page 22). According to Novartis, vaccine production based on cell cultures promises advantages over traditional chicken-egg-based methods.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment